Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Barclays Analyst Says

Edwards Lifesciences (NYSE:EW) had its price objective boosted by research analysts at Barclays from $110.00 to $120.00 in a report released on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 17.75% from the company’s current price.

A number of other research analysts have also recently issued reports on EW. Evercore reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a report on Friday, October 23rd. UBS Group reissued a “buy” rating and issued a $110.00 target price (up from $90.00) on shares of Edwards Lifesciences in a research report on Thursday, October 8th. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Raymond James Financial lifted their price target on Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Truist Financial set a $113.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $108.88.

Edwards Lifesciences Stock Up 1.1%

Edwards Lifesciences stock traded up $1.09 during midday trading on Thursday, reaching $101.91. The company’s stock had a trading volume of 5,112,546 shares, compared to its average volume of 4,098,582. The stock’s 50-day simple moving average is $88.92 and its 200-day simple moving average is $85.78. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $104.17. The stock has a market capitalization of $58.68 billion, a P/E ratio of 57.58, a PEG ratio of 2.44 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The business had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter in the previous year, the firm earned $0.67 earnings per share. The company’s revenue was up 10.5% on a year-over-year basis. On average, sell-side analysts expect that Edwards Lifesciences will post 3.01 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,045 shares of company stock valued at $451,596 in the last ninety days. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EW. Legacy Trust grew its stake in shares of Edwards Lifesciences by 1.4% during the 3rd quarter. Legacy Trust now owns 7,409 shares of the medical research company’s stock worth $682,000 after purchasing an additional 104 shares during the period. Flagship Harbor Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1.2% during the 3rd quarter. Flagship Harbor Advisors LLC now owns 10,615 shares of the medical research company’s stock worth $916,000 after acquiring an additional 125 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Edwards Lifesciences by 1.8% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 7,268 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 132 shares in the last quarter. Calamos Wealth Management LLC increased its stake in shares of Edwards Lifesciences by 6.1% in the 3rd quarter. Calamos Wealth Management LLC now owns 2,438 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 141 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in Edwards Lifesciences by 1.4% in the 3rd quarter. Signaturefd LLC now owns 10,034 shares of the medical research company’s stock worth $866,000 after purchasing an additional 142 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
• Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
• Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
• Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.

The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.